Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

First-Ever Platform Trial for Progressive Supranuclear Palsy Enrolls Its Inaugural Participant

13 August 2026 · By · Wire by Fusion42

Published

13 August 2026

Topic

opportunities

◆ Sectors

BiotechDrug Discovery

◆ Geography

United States

◆ Source

Read at neurologylive.com →

◆ Verified

Fusion42 · 13 August 2026 · Fusion42 review

The first-ever platform trial for Progressive Supranuclear Palsy (PSP) has enrolled its inaugural participant, introducing a master-protocol perpetual platform that enables scalable addition of new PSP therapeutics based on the HEALEY ALS platform.

This Wire brief sits within Fusion42's coverage of Biotech and Drug Discovery.

◆ ◆ The Wire takeaway

Biotech founders in neurodegenerative diseases can move now to align with scalable platform trial models that accelerate therapeutic development. This new trial structure challenges traditional slow, costly studies and opens access to continuous drug candidates for PSP.

◆ Coverage

1 source · 13 Aug 2026

◆ Related on Wire

◆ Topics

BiotechDrug Discoveryplatform-trialpspbiotech-innovationclinical-trialsneurodegenerative